Evidence map›Paper›PMID 40259106›Full record

ArticleInternational journal of clinical oncology2025

Prognostic factors and effect of existing predictive models in oligo-metastatic urothelial carcinoma (YUSHIMA study).

Kenji Tanabe, Soichiro Yoshida, Tomoki Kimura, Yuya Maezawa, Kensaku Ishihara, Naoki Inoue, Keita Izumi, Motohiro Fujiwara, Masahiro Toide, Takanobu Yamamoto and 8 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Kenji TanabeDepartment of Urology, Institute of Science Tokyo, Bunkyo-Ku, 1 - 5- 45, Yushima, Bunkyo-ku, Tokyo, 113 - 8510, Japan.ORCID http://orcid.org/0000-0002-4122-5279
Soichiro YoshidaDepartment of Urology, Institute of Science Tokyo, Bunkyo-Ku, 1 - 5- 45, Yushima, Bunkyo-ku, Tokyo, 113 - 8510, Japan. s-yoshida.uro@tmd.ac.jp.
Tomoki KimuraDepartment of Urology, Saitama Red Cross Hospital, Saitama, Japan.
Yuya MaezawaDepartment of Urology, Tsuchiura Kyodo General Hospital, Tsuchiura-shi, Ibaraki, Japan.
Kensaku IshiharaDepartment of Urology, Soka Municipal Hospital, Soka-shi, Saitama, Japan.
Naoki InoueDepartment of Urology, JA Toride Medical Hospital, Toride-shi, Ibaraki, Japan.
Keita IzumiDepartment of Urology, Dokkyo Medical University Saitama Medical Center, Koshigaya-Shi, Saitama, Japan.
Motohiro FujiwaraDepartment of Urology, Teikyo University Hospital, Mizonokuchi, Kawasaki-shi, Kanagawa, Japan.
Masahiro ToideDepartment of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan.
Takanobu YamamotoDepartment of Urology, Tokyo Metropolitan Tama-Nambu Chiiki Hospital, Tama-shi, Tokyo, Japan.
Sho UeharaDepartment of Urology, Showa General Hospital, Kodaira-shi, Tokyo, Japan.
Saori ArakiDepartment of Urology, Kohnodai Hospital, Ichikawa-shi, Chiba, Japan.
Masaharu InoueDepartment of Urology, Saitama Cancer Center, Kita-Adachi-Gun, Ina-machi, Saitama, Japan.
Ryoji TakazawaDepartment of Urology, Tokyo Metropolitan Ohtsuka Hospital, Toshima-ku, Tokyo, Japan.
Noboru NumaoDepartment of Urology, Cancer Institute Hospital, Koto-ku, Tokyo, Japan.
Yukihiro OhtsukaDepartment of Urology, Japanese Red Cross Omori Hospital, Ota-ku, Tokyo, Japan.
Hajime TanakaDepartment of Urology, Institute of Science Tokyo, Bunkyo-Ku, 1 - 5- 45, Yushima, Bunkyo-ku, Tokyo, 113 - 8510, Japan.
Yasuhisa FujiiDepartment of Urology, Institute of Science Tokyo, Bunkyo-Ku, 1 - 5- 45, Yushima, Bunkyo-ku, Tokyo, 113 - 8510, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOligo-metastatic urothelial carcinoma (OMUC), characterized by a limited number of metastases, demonstrates better survival outcomes compared to poly-metastatic urothelial carcinoma (PMUC), but some patients with OMUC exhibit poor prognosis. However, a comprehensive analysis of prognostic factors in OMUC remains lacking. This study aimed to determine prognostic factors in patients with OMUC from a multicenter dataset and evaluate the effect of existing predictive models.

methodsThis retrospective study included 443 patients with metastatic urothelial carcinoma (MUC) from 15 institutions (YUSHIMA study). OMUC involved cases with three or fewer metastases. Clinical data were analyzed for associations with overall survival (OS) utilizing Cox regression models. The effect of existing predictive models (Bajorin, Bellmunt, and Apolo) on OMUC prognosis was evaluated.

resultsPatients with OMUC (n = 182) demonstrated better Eastern Cooperative Oncology Group-performance status (ECOG-PS) and lower visceral metastasis frequency compared to PMUC (n = 261). Patients with OMUC exhibited a median OS of 26.1 months vs. 13.7 months for PMUC (p < 0.01). Poor ECOG-PS, liver metastasis, and hypoalbuminemia appeared as independent poor prognostic factors for OS in OMUC. The Bajorin, Bellmunt, and Apolo models significantly correlated with OS in patients with OMUC (p < 0.01, for all).

conclusionKnown prognostic factors for MUC were confirmed as significant prognostic factors for OS in OMUC, and existing prognostic models applied to OMUC. These results are expected to contribute to developing more effective treatment strategies for OMUC.

Indexed as

Carcinoma, Transitional CellUrologic NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm MetastasisPrognosisRetrospective StudiesUrotheliumMetastasisOligo-metastasisPrognosisSurvivalUrothelial carcinoma

Identifiers

PMID40259106

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.